共 41 条
Long-term outcome and tolerability of the ketogenic diet in drug-resistant childhood epilepsy-The Austrian experience
被引:75
作者:
Dressler, Anastasia
[1
]
Stoecklin, Benjamin
[1
,3
]
Reithofer, Eva
[1
]
Benninger, Franz
[2
]
Freilinger, Michael
[1
]
Hauser, Erwin
[1
]
Reiter-Fink, Edith
[1
]
Seidl, Rainer
[1
]
Trimmel-Schwahofer, Petra
[1
]
Feucht, Martha
[1
]
机构:
[1] Med Univ Vienna, Dept Paediat, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Child & Adolescent Psychiat, A-1090 Vienna, Austria
[3] Univ Childrens Hosp Basel, Dept Neuropaediat, Basel, Switzerland
来源:
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
|
2010年
/
19卷
/
07期
关键词:
Ketogenic diet;
Childhood;
Epilepsy;
ANTIEPILEPTIC DRUGS;
EFFICACY;
CHILDREN;
SAFETY;
D O I:
10.1016/j.seizure.2010.06.006
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Purpose: To evaluate the long-term efficacy/tolerability of the ketogenic diet (KD) in paediatric drug-resistant epilepsies. Methods: Data from children who were treated between 1999 and 2008 and had continuous follow-up of at least 6 months after initiation of the KD were analysed retrospectively. Response was defined as >= 50% seizure reduction. Treatment effects on EEG, developmental outcome and the "outcome-predictive" value of various clinical factors were also assessed. Results: 50 children (22 boys; mean age 4.5 years +/- 3.55) were included. Mean follow-up was 3.93 +/- 2.95. 50% of the patients were responders, 48% of them became seizure free. 50% were non-responders, 20% of them deteriorated. In responders, EEG background activity improved significantly (p = 0.014) and a significantly lower rate of epileptic discharges (p = 0.009) was seen after 6 months. In addition, neurological examination findings demonstrated significant developmental progress (p = 0.038). Favourable treatment outcome was associated with a shorter disease duration (p = 0.025) and generalised tonic clonic seizures (p = 0.059). No further significant outcome predictors were detected. However, response was 44% in patients with infantile spasms, 62.5% in those with Dravet syndrome and 50% in Lennox-Gastaut-syndrome. Side effects occurred in 28%, but discontinuation of the KD was not required in any case. They most often observed with concomitant topiramate (p = 0.001) and valproate (p = 0.046). Conclusion: Despite the retrospective nature of the study and the inhomogeneous patient sample, we found good long-term effects of the KD on seizure frequency, EEG and neurological development. (C) 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:404 / 408
页数:5
相关论文